SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-361060
Filing Date
2021-12-17
Accepted
2021-12-17 16:02:03
Documents
15
Period of Report
2021-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d262325d8k.htm   iXBRL 8-K 34482
2 EX-99.1 d262325dex991.htm EX-99.1 10280
3 EX-99.2 d262325dex992.htm EX-99.2 17983
7 GRAPHIC g262325g1217150858043.jpg GRAPHIC 3099
  Complete submission text file 0001193125-21-361060.txt   203979

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lyel-20211215.xsd EX-101.SCH 2872
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20211215_lab.xml EX-101.LAB 18124
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20211215_pre.xml EX-101.PRE 11392
8 EXTRACTED XBRL INSTANCE DOCUMENT d262325d8k_htm.xml XML 3358
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 211501444
SIC: 2834 Pharmaceutical Preparations